Shares of Voyager Therapeutics were down in trading after the company announced a clinical hold was placed on an experimental gene therapy treatment for Huntington’s disease before heading into the clinic.
With $29 million in the company’s pocket, biotech Libra Therapeutics launched to take on neurodegenerative disease, with three pre-clinical programs ready to roll.
Vaccinex Inc. will pair the company’s lead asset pepinemab with Merck & Co.’s vaunted checkpoint inhibitor Keytruda.
Amylyx Pharmaceuticals Inc. announced the publication of results from the pivotal CENTAUR trial evaluating AMX0035 – an investigational neuroprotective therapy designed to reduce the death and dysfunction of motor neurons – in people with amyotrophic lateral sclerosis (ALS) in the New England Journal of Medicine.
Cambridge, Massachusetts-based Yumanity Therapeutics and Boston-based Proteostasis Therapeutics announced plans to merge. The combined company will operate after the deal as Yumanity Therapeutics, and will focus on protein misfolding and neurodegenerative diseases.
Framingham, Massachusetts-based Alzheon was awarded a $47 million grant over five years from the U.S. National Institute on Aging (NIA), part of the National Institutes of Health, to assist with a Phase III clinical trial of ALZ-801.
Dragonfly Therapeutics announced a new research collaboration with Bristol Myers Squibb to discover and develop Dragonfly’s novel immunotherapies for multiple sclerosis and neuro-inflammation targets.
Yumanity Therapeutics and Merck signed a strategic research and license deal for two Yumanity programs. The two preclinical programs are for amyotrophic lateral sclerosis (ALS) and frontotemporal lobar dementia (FTLD).
While COVID-19 has caused the delay in some clinical trials and hampered workflow in the biopharma industry due to social distancing concerns, some companies have pushed ahead with initial public offerings (IPO) in hopes of securing investor monies to support drug and business development.
Biopharmaceutical companies need to look beyond the usual targets when addressing neurodegenerative disorders and also must work to correlate genetic changes to cognitive changes in patients, according to panelists at BIO’s on-demand session, “Battle of the Brains: Rethinking Neurodegenerative Disease Treatment.”